CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Itraconazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03722173
NCT03722173Phase 1Completed

Relative Bioavailability of a Single Oral Dose of BI 894416 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, One-way Crossover Study)

Boehringer Ingelheim·interventional·Posted Oct 26, 2018·Updated Aug 14, 2023

In Brief

A Phase 1 clinical trial evaluating Itraconazole and BI 894416 for Healthy. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The main objective of this trial is to investigate the relative bioavailability of BI 894416 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test,T) as compared to when given alone as oral single dose (Reference, R).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 26, 2018
Enrollment StartNov 13, 2018
Primary CompletionDec 14, 2018
Study CompletionDec 18, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.7 years ago

Interventions

Itraconazoledrug

Oral solution

BI 894416drug

Tablet